Newcomer Mark sold $1.8M of PAYS
Newcomer Mark (CEO) sold 150,000 shares of Paysign, Inc. (PAYS) at $11.88 ($1.78M total) on 2026-08-06 under a Rule 10b5-1 trading plan.
Paysign, Inc.
Newcomer Mark (CEO) sold 150,000 shares of Paysign, Inc. (PAYS) at $11.88 ($1.78M total) on 2026-08-06 under a Rule 10b5-1 trading plan.
Paysign, Inc. (PAYS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 paysign_ex9901.htm EARNINGS RELEASE Exhibit 99.1 Earnings Release Paysign Reports Record Second Quarter 2026 Revenue of $28.3 Million, Up 48%; Raises Full-Year Outlook Growth Driven by Continued Momentum in Plasma and Patient Affordability Businesses Mix Shift and Expen
Mina Bruce A sold 20,000 shares of Paysign, Inc. (PAYS) at an average of $7.10 ($7.10–$7.10, $0.14M total) across 2 trades over 2026-06-01 to 2026-06-11.
Over the past 7 days, alphai's AI scored 1 news story mentioning PAYS (Paysign, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent PAYS coverage spans insider activity, financial news and earnings.
In the last 30 days, PAYS insiders filed 4 SEC Form 4 transactions — no purchases and 4 sales ($2.8M). The most active reporter was Herman Joan M, EVP, Operations, with 2 filings. 100% of activity was filed under pre-arranged Rule 10b5-1 plans.
The filing discloses an insider open-market sale, which can modestly affect near-term sentiment but is mitigated by the stated 10b5-1 pre-arranged plan.
Q2 beat plus raised guidance and margin expansion signals improving profitability and operating leverage, likely supporting near-term sentiment and estimates.
This is a routine insider sale with no stated 10b5-1 plan, but it does not disclose new company fundamentals.
Routine insider selling under a 10b5-1 plan, likely limited incremental signal, but can modestly affect near-term sentiment.
Routine 10b5-1 insider sale provides limited signal, but confirms ongoing insider liquidity activity at a specific price and date.
alphai scores every news story that mentions PAYS with an AI model for sentiment and relevance, and aggregates insider trades from Paysign, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Newcomer Mark (CEO) sold 150,000 shares of Paysign, Inc. (PAYS) at $11.88 ($1.78M total) on 2026-08-06 under a Rule 10b5-1 trading plan.
2 min readPaysign, Inc. (PAYS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 paysign_ex9901.htm EARNINGS RELEASE Exhibit 99.1 Earnings Release Paysign Reports Record Second Quarter 2026 Revenue of $28.3 Million, Up 48%; Raises Full-Year Outlook Growth Driven by Continued Momentum in Plasma and Patient Affordability Businesses Mix Shift and Expen
6 min readMina Bruce A sold 20,000 shares of Paysign, Inc. (PAYS) at an average of $7.10 ($7.10–$7.10, $0.14M total) across 2 trades over 2026-06-01 to 2026-06-11.
2 min readHerman Joan M (EVP, Operations) sold 59,904 shares of Paysign, Inc. (PAYS) at an average of $8.64 ($8.60–$8.69, $0.52M total) across 2 trades over 2026-07-15 to 2026-07-16 under a Rule 10b5-1 trading plan.
2 min readHerman Joan M (EVP, Operations) sold 100,000 shares of Paysign, Inc. (PAYS) at $8.01 ($0.80M total) on 2026-06-26 under a Rule 10b5-1 trading plan.
2 min readHerman Joan M (EVP, Operations) sold 29,202 shares of Paysign, Inc. (PAYS) at $8.00 ($0.23M total) on 2026-06-01 under a Rule 10b5-1 trading plan.
2 min readHerman Joan M (EVP, Operations) sold 22,534 shares of Paysign, Inc. (PAYS) at $7.01 ($0.16M total) on 2026-05-26 under a Rule 10b5-1 trading plan.
2 min readPaysign, Inc. (NASDAQ:PAYS) experienced a 26.4% decrease in short interest during April, reducing the total to 1,685,717 shares. This represents approximately 4.0% of the company's shares sold short, resulting in a short-interest ratio of 1.7 days. Institutional investors hold 25.89% of the stock, with several firms increasing their stakes, and analysts maintain a "Moderate Buy" rating with a consensus target price of $9.42 amidst recent mixed earnings results.
2 min readPaysign, Inc. (NASDAQ: PAYS) announced strong financial results for the fourth quarter and full-year 2025, driven significantly by its patient affordability offerings. The company reported a 40.5% increase in total revenues to $82.0 million for the full year, with patient affordability revenue surging by 167.8%. Paysign also provided an optimistic outlook for 2026, projecting continued revenue growth and margin expansion, with anticipated net income nearly doubling.
4 min readPaysign, Inc. (NASDAQ:PAYS) has received a consensus "Moderate Buy" rating from analysts, with an average 12-month price target of $8.56. Recent analyst updates include a $9 target from DA Davidson and a "buy" upgrade from Wall Street Zen. The company reported in-line Q earnings and beat revenue expectations, setting FY2025 EPS guidance of $0.120-$0.130.
3 min read